Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
Phase 3 N=225 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack
Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants
Phase 4 N=203 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…
Phase 1 N=20 Reperfusion With Cooling in Cerebral Acute Ischemia
Stroke, Acute
Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants
Phase 2 N=36 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
N/A N=12,012 Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
Stroke
Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers
N/A N=1,560 Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
N/A N=2,502 Carotid Revascularization Endarterectomy Versus Stenting Trial
Atherosclerosis · Stroke · Carotid Stenosis
Primary: Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years…
Phase 2 N=84 Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
Acute Cerebral Stroke Within 12 Hours for the First Time
Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale
N/A N=10 Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke
Stroke, Acute
Primary: Safety Outcome: Rate of Symptomatic Intracranial Hemorrhage (SICH) in the Active Treatment Arms Compared to Sham Arm — 0; 1; 0 Participants
N/A N=4,071 China Antihypertensive Trial in Acute Ischemic Stroke
Ischemic Stroke
Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants
Phase 1 N=57 The Capillary Index Score Trial
Acute Stroke · Brain Ischemia · Ischemic Stroke
Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants
Phase 4 N=60 Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Ischemic Stroke
Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 2 N=125 Study to Assess the Safety and Effectiveness of the Penumbra System
Stroke
Primary: Percentage of Participants With Revascularization of the Occluded Target Vessel — 81.2 Percentage of Participants
Phase 2 N=20 Safety of Intravenous Thrombolytics in Stroke on Awakening
Stroke
Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment — 0 participants
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
Phase 1 N=23 Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke
Stroke
Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
N/A N=101 Canadian Pradaxa Acute Stroke Safety Study
Ischemic Attack, Transient · Stroke
Primary: Symptomatic Hemorrhagic Transformation Rate (PH2) — 0; 0 Participants
N/A N=42,188 Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
Stroke
Primary: Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous…
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=126 Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Cerebrovascular Accident · Moyamoya Disease
Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…